Le Lézard
Classified in: Health
Subject: SHA

Repurchased Shares in Karo Pharma During Week 25 2018


STOCKHOLM, June 25, 2018 /PRNewswire/ -- During the period 18 June 2018 to 21 June 2018, Karo Pharma AB (publ) (LEI code 213800G54Z51LOPGTA79) has repurchased in total 383 289 own shares (ISIN:  SE00007464888). The repurchases form part of the SEK 86.3 million share repurchase programme that Karo Pharma announced on 18 June 2018. The share repurchase programme, which runs between 18 June 2018 and 31 August 2018, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052.

During the period 18 June 2018 ? 21 June 2018, shares in Karo Pharma have been repurchased as follows.

Date

 

Aggregated daily volume (number of shares)

 

Weighted averages share price per day (SEK)

 

Total daily transaction value (SEK)

 

18 June 2018

107 200

29.640365

3 177 447

19 June 2018

89 250

29.363100

2 620 657

20 June 2018

86 839

29.366600

2 550 166

21 June 2018

100 000

29.360800

2 936 080

All acquisitions have been carried out on Nasdaq Stockholm by Swedbank in cooperation with Kepler Cheuvreux SA on behalf of Karo Pharma. Following the above acquisitions, Karo Pharma's holding of own shares amounts to 383,289 shares as of 21 June 2018. The total number of shares in Karo Pharma is 164,332,782.

The total volume of Karo Pharma's shares which have been bought back within the repurchase programme from 18 June 2018 until and including 21 June 2018 amounts to 383 289 shares. In total a maximum of 2 464 990 shares may be repurchased. For information about all transactions in the buy-back programme see the following link to Nasdaq Stockholm's website: http://www.nasdaqomx.com/transactions/markets/nordic/corporate-actions/stockholm/repurchases-of-own-shares.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Peter Blom
CEO
+46-(0)-70-655-56-98
[email protected]

ABOUT KARO PHARMA
Karo Pharma is a Specialty Pharma company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.

The information was submitted for publication, through the above contact person´s agency, at 08.00 CEST on 25 June 2018. This press release is also available at www.karopharma.se and www.newsroom.cision.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/karo-pharma/r/repurchased-shares-in-karo-pharma-during-week-25-2018,c2556181

The following files are available for download:

http://mb.cision.com/Main/72/2556181/865549.pdf

Press release (PDF)


These press releases may also interest you

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 07:00
R&D Leader and software architect with more than three decades of experience designing, developing,...

at 07:00
Gordian Biotechnology, an in vivo drug discovery and development...

at 07:00
GeBBS Healthcare Solutions, Inc.(ChrysCapital portfolio company) a leading provider of technology enabled Revenue Cycle Management (RCM) & Risk Adjustment Solutions for Healthcare Providers and Payers, announced the acquisition of CCD Health, a...

at 07:00
Many American children...



News published on and distributed by: